STIFEL FINANCIAL CORP - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.

Quarter-by-quarter ownership
STIFEL FINANCIAL CORP ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$254,862
-34.9%
12,354
-6.8%
0.00%
-100.0%
Q2 2023$391,272
+25.5%
13,259
-2.0%
0.00%
Q1 2023$311,663
-16.4%
13,527
+0.9%
0.00%
-100.0%
Q4 2022$372,849
-10.2%
13,407
-1.0%
0.00%0.0%
Q3 2022$415,000
+8.4%
13,548
+4.3%
0.00%0.0%
Q2 2022$383,000
-12.8%
12,990
-4.8%
0.00%0.0%
Q1 2022$439,000
-27.9%
13,640
-0.1%
0.00%0.0%
Q4 2021$609,000
-17.7%
13,655
-6.9%
0.00%0.0%
Q3 2021$740,000
-27.7%
14,667
+12.4%
0.00%
-50.0%
Q2 2021$1,024,000
+38.4%
13,050
+0.6%
0.00%
+100.0%
Q1 2021$740,000
+47.1%
12,966
+115.7%
0.00%0.0%
Q4 2020$503,000
+123.6%
6,011
-4.1%
0.00%
Q3 2020$225,000
-4.7%
6,271
-54.0%
0.00%
-100.0%
Q1 2020$236,000
+14.0%
13,621
+14.5%
0.00%
Q4 2019$207,000
+16.3%
11,895
+2.8%
0.00%
Q3 2019$178,000
-25.8%
11,5750.0%0.00%
-100.0%
Q2 2019$240,00011,5750.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Crestline Management, LP 19,462,500$339,037,00035.95%
Euclidean Capital LLC 323,749$27,117,0005.74%
Flagship Pioneering Inc. 2,730,263$228,687,0004.16%
Casdin Capital, LLC 1,310,000$109,726,0003.25%
A.R.T. Advisors, LLC 6,173$517,0002.39%
MARK ASSET MANAGEMENT LP 172,040$14,410,0001.73%
Temasek Holdings (Private) Ltd 4,410,457$369,420,0001.59%
Integral Health Asset Management, LLC 57,500$4,816,0001.43%
GILDER GAGNON HOWE & CO LLC 3,219,843$269,694,0001.34%
IRONWOOD INVESTMENT MANAGEMENT LLC 19,365$1,622,0000.95%
View complete list of DENALI THERAPEUTICS INC shareholders